Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in previously treated metastatic colorectal cancer
NCT00397878Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Nov 2011
- Countries
- 1
01
Overview
Phase 2, open-label trial of saracatinib in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 4 months. Started Nov 2006; status: terminated.
02
Drugs
saracatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00397878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397878.